N-terminal splice variants of the type I PACAP receptor: Isolation, characterization and ligand binding/Sslectivity determinants

Journal of Neuroendocrinology

Volumn 11, Issue 12, 1999, Pages 941-949

  Dautzenberg, Frank M ^a,b   Mevenkamp, G ^b   Wille, S ^b   Hauger, R L ^a,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cyclic AMP; Ligand binding; Receptor cloning; Receptor expression

Indexed keywords

COMPLEMENTARY DNA; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CELL SPECIFICITY; CEREBELLUM; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; KIDNEY CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BINDING SITES; BINDING, COMPETITIVE; CEREBRAL CORTEX; CLONING, MOLECULAR; CYCLIC AMP; HUMANS; KIDNEY; LIGANDS; MOLECULAR SEQUENCE DATA; NEURONS; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, PITUITARY HORMONE; RETINOBLASTOMA; RNA SPLICING; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFECTION; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032724068     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2826.1999.00411.x     Document Type: Article

References (60)

1. Miyata A, Arimura A. Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolution of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-574.
2. Miyata A, Jiang L. Dahl RD, Kitada C, Kubo K. Fujino M, Minamino N. Arimura A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 1989; 170: 643-648.
3. Arimura A, Somogyvari-Vigh A, Weill C, Fiore RC, Tatsuno I. Bay V, Brenneman DE. PACAP functions as a neurotrophic factor. Ann NY Acad Sci 1994; 739: 228-243.
4. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 1995; 16: 53-88.
5. Lu N, DiCieco-Bloom E. Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proceed Natl Acad Sci USA 1997; 94: 3357-3362.
6. Wasehek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM, Rodriguez WI. Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. Proc Natl Acad Sci USA 1998; 95: 9602-9607.
7. Villalba M, Bockart J, Journot L. Pituitary adenylate cyclase-activating polypeptide (PACAP38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein Kinase (MAP Kinase) pathway. J Neurosci 1997; 17: 83-90.
8. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992; 8: 811-819.
9. Inagaki N, Yoshida H, Mizuta M, Mizuno N. Fujii Y, Gonoi T, Miyazaki JI, Seino S. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proceed Natl Acad Sci USA 1994; 91: 2679-2683.
10. Rawlings ST, Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocrine Rev 1996; 17: 4-29.
11. Harmar T, Lutz E. Multiple receptors for PACAP and VIP Trends Pharmacol Sci 1994; 15: 97-99.
12. Pisegna JR, Wank SA. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. J Biol Chem 1996; 271: 17267-17674.
13. Pisegna JR, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type 1 receptor. Proceed Natl Acad Sci USA 1993; 90: 6345-6349.
14. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockart J, Seeburg PH. Journot L. Differential signal transduction by five splice variants of the PACAP receptor Nature 1993; 365: 170-175.
15. Hashimoto H, Ishihara T, Shigemoto R, Mori K, Nagata S. Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 1993; 11: 333-342.
16. Morrow JA, Lutz EM, West KM, Fink G, Hamar AJ. Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP). FEBS Lett 1993; 329: 99-105.
17. Svoboda M, Tastenoy M, Ciccarelli E, Stievenart M, Christophe J. Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor. Biochem Biophys Res Commun 1993; 195: 881-888.
18. Hashimoto H, Yamamoto K, Hagigara N. Ogawa N, Nishino A, Aino H, Nogi H, Imanishi K, Matsuda T, Baba A. cDNA cloning of a mouse pituitary adenylate cyclase-activating polypeptide receptor. Biochim Biophys Acta 1996; 1281: 129-133.
19. Miyamoto Y, Habata Y, Ohtaki T, Masuda Y, Ogi K. Onda H, Fujino M. Cloning and expression of a complementary DNA encoding the bovine receptor for pituitary adenylate cyclase-activating polypeptide (PACAP). Biochim Biophys Acta 1994; 1218: 297-307.
20. Xiong Y, Xie LY, Abou-Samra AB. Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. Endocrinology 1995; 136: 1828-1834.
21. Nabhan C, Xiong Y, Xie LY, Abou-Samra AB. The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-I cells, is not well coupled to the G protein(s). Biochem Biophys Res Commun 1995; 212: 1015-1021.
22. Shyu JF, Inoue D, Baron R, Horne WC. The deletion of 14 amino acids in the seventh transmembrane domain of a naturally occurring calcitonin receptor isoform alters ligand binding and selectively abolishes coupling to phospholipase C. J Biol Chem 1996; 271: 31127-31134.
23. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989; 342: 926-929.
24. Reisine T, Kong H, Raynor K, Yano H, Takeda J, Yasuda K, Bell GI. Splice variant of the somatostatin receptor 2 subtype, somatostatin receptor 2B, couples to adenylyl cyclase. Mol Pharmacol 1993; 44: 1016-1020.
25. 2 receptor isoforms in human platelets, J Clin Invest 1996; 97: 949-956.
26. Parker EM, Swigart P, Nunnally MH, Perkins JP, Ross EM. Carboxyl-terminal domains in the avian bo-adrenergic receptor that regulate agonist-promoted endocytosis. J Biol Chem 1995; 270: 6482-6487.
27. Zimprich A, Simon T. Höllt V. Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. FEBS Lett 1995; 359: 142-146.
28. Miyake A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem Biophys Res Commun 1995; 208: 230-237.
29. Ross PC, Kostas CM. Ramabhadran TV. A variant of the human corticotropin-releasing factor (CRF) receptor: cloning, expression and pharmacology. Biochem Biophys Res Commun 1994; 205: 1836-1842.
30. + channels. Proceed Natl Acad Sci USA 1998; 95: 14991-14996.
31. Journot L, Spengler D, Pantaloni C, Dumuis A, Sebben M, Bockaert J. The PACAP receptor: generation by alternative splicing of functional diversity among G protein-coupled receptors in nerve cells. Sem Cell Biol 1994; 5: 263-272.
32. Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J, Journot L. Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP27 and PACAP38 in phospholipase C activation. J Biol Chem 1996; 271: 22146-22151.
33. Scaldaferri L, Arora K, Lee SH, Catt KJ, Moretti C. Expression of PACAP and its type-1 receptor isoforms in the rat ovary. Mol Cell Endocrinol 1996; 117: 227-232.
34. Chatterjee TK, Sharma RV, Fisher RA. Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem 1996; 271: 32226-33222.
35. Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P, Laburthe M. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem Biophys Res Commun 1995; 206: 246-252.
36. Gaudin P. Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 1995; 211: 901-908.
37. Holtmann MH, Hadac EM, Miller LJ. Critical contributions of aminoterminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J Biol Chem 1995; 270: 14394-14398.
38. Hashimoto H, Ogawa N, Hagihara N. Yamamoto K, Imanishi K, Nogi H. Nishino A, Fujita T. Matsuda T, Nagata S, Baba A. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol Pharmacol 1997; 52: 128-135.
39. Nicole P, Du K, Couvineau A, Laburthe M. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. J Pharmacol Exp Ther 1998; 284: 744-750.
40. Dautzenberg FM, Dietrich K, Palchaudhuri MR. Spiess J. Identification of two corticotropin-releasing factor receptors with high ligand selectivity from Xenopus laevis: unusual pharmacology of type I receptor. J Neurochem 1997; 69: 1640-1649.
41. Palchaudhuri MR. Wille S. Mevenkamp G, Speiss J, Fuchs E, Dautzenberg FM. Corticotropin-releasing factor receptor type 1 from Tupaia belangeri: cloning, functional expression and tissue distribution. Eur J Biochem 1998; 258: 78-84.
42. Palchaudhuri MR, Hauger RL, Wille S, Fuchs E, Dautzenberg FM. Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri. J Neuroendocrinol 1999; 11: 419-428.
43. Dautzenberg FM, Wille S, Lohmann R, Spiess J. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proceed Natl Acad Sci USA 1998; 95: 4941-4945.
44. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 220-239.
45. Lundberg KS, Shoemaker DD, Adams MWW. Short JM, Sorge JA, Mathur EJ. High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus. Gene 1991; 108: 1-6.
46. Chatterjee TK, Liu X, Davisson RL, Fisher RA. Genomic organization of the rat pituitary adenylate cyclase-activating polypeptide receptor gene. J Biol Chem 1997; 272: 12122-12131.
47. Tsai-Morris CH, Buczko E. Geng Y, Gamboa-Pinto A. Dufau ML. The genomic structure of the rat corticotropin releasing factor receptor: a member of the class II G protein-coupled receptors. J Biol Chem 1996; 271: 14519-14525.
48. Sakai K, Yamada M. Horiba N, Wakui M, Demura H, Suda T. The genomic organization of the human corticotropin-releasing factor type-1 receptor. Gene 1998; 219: 125-130.
49. Sugita S, Ichtchenko K, Khvotchev M, Sudhof TC. α-Latrotoxin receptor CIRL/latrophilin 1 (CL1) defines an unusual family of ubiquitous G-protein-coupled receptors. J Biol Chem 1998; 273: 32715-32724.
50. Qi LJ, Leung AT, Xiong Y, Marx KA, Abou-Samra AB. Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry 1997:36: 12442-12448.
51. Lee C, Gardella TJ, Abou-Samra AB, Nussbaum SR, Segre GV, Potts JT Jr, Kronenberg HM, Juppner H. Role of the extracellular regions of the parathyroid hormone (PTH) PTH-related peptide receptor in hormone binding. Endocrinology 1994; 135: 1488-1495.
52. Wille S, Sydow S, Palchaudhuri MR. Speiss J, Dautzenberg FM, Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor I that are important determinants of high affinity ligand binding. J Neurochem 1999; 72: 388-395.
53. Perrin MH, Sutton S. Bain D. Berggren WT. Vale WW. The first extracellular domain of corticotropin-releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology 1998; 139: 566-570.
54. Cao YJ, Gimpl G, Fahrenholz F, The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. Biochem Biophys Res Commun 1995; 212: 673-680.
55. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P. Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP-1 and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann NY Acad Sci 1996; 805: 94-111.
56. Lutz EM, MacKenzie CJ, Morrow J, Mitchell R, Bennie J, Carroll S, Clark E, Harmar AJ, Chimaeric VIP. 2/PACAP. receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1. Ann NY Acad Sci 1996; 805: 574-578.
57. Delporte C, Poloezek P, de Neef P. Vertongen P, Ciccarelli E, Svoboda M, Herchuelz A, Winand J, Robberecht P, Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type 1 PACAP receptor. Mol Cell Endocrinol 1995; 107: 71-76.
58. Olianas MC, Ennas MG, Lampis G, Onali P. Presence of pituitary adenylate cyclase-activating polypeptide receptors in Y-79 human retinoblastoma cells. J Neurochem 1996; 67: 1293-1300.
59. Olianas MC, Ingianni A, Sogos V, Onali P. Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors and PACAP in human fetal retina. J Neurochem 1997; 69: 1213-1218.
60. D'Agata V, Cavallaro S. Functional and molecular expression of PACAP/VlP receptors in the rat retina. Mol Brain Res 1998; 54: 161-164.